The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders
Panos Stathopoulos, Marinos C. Dalakas
Abstract
INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) are characterized in the majority of cases by the presence of IgG1 autoantibodies against aquaporin 4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG), both capable of activating complement. AREAS COVERED: We review evidence of complement involvement in NMOSD pathophysiology from pathological, in vitro, in vivo, human studies, and clinical trials. EXPERT OPINION: , are rapidly changing the therapeutic algorithm in NMOSD, a previously difficult-to-treat autoimmune neurological disorder.
Topics & Concepts
EculizumabNeuromyelitis opticaMedicineImmunologyComplement systemMyelin oligodendrocyte glycoproteinAutoantibodyMultiple sclerosisAntibodyExperimental autoimmune encephalomyelitisMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSystemic Lupus Erythematosus Research